Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Venous thromboembolism (VTE) is associated with almost 300,000 deaths per year in the United States. Novel oral anticoagulants (NOACs) offer an alternative to warfarin-based therapy without monitoring requirements and with fewer drug and food interactions. Edoxaban, a direct Xa inhibitor, is approved by the Food and Drug Administration (FDA), based upon results of the Hokusai-VTE Phase 3 trial. The trial demonstrated that edoxaban administered once daily after initial treatment with heparin was non-inferior in reducing the risk of VTE recurrence and caused significantly less major and clinically relevant non-major (CRNM) bleeding compared to warfarin. The objective of this study was to evaluate the cost-effectiveness of edoxaban versus warfarin for the treatment of adults with VTE. METHODS: A cost-effectiveness model was developed using patient-level data from the Hokusai-VTE trial, clinical event costs from real-world databases, and drug acquisition costs for warfarin of $0.36 and edoxaban of $9.24 per tablet. RESULTS: From a U.S. health-care delivery system perspective, the incremental cost-effectiveness ratio (ICER) was $22,057 per quality adjusted life year (QALY) gained. Probabilistic sensitivity analysis showed that edoxaban had an ICER <$50,000 per QALY gained relative to warfarin in 67% of model simulations. The result was robust to variation in key model parameters including the cost and disutility of warfarin monitoring. CONCLUSION: Despite its higher drug acquisition cost, edoxaban is a cost-effective alternative to warfarin for the treatment of VTE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“All of them suggested that DOACs are costeffective relative to VKA. 100,104-116”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Self-citationOral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583 · cited 1×
“[38–40] There is also wide variation in treatment duration, the proportion of unprovoked/provoked VTE cases, the number of PE patients and the disease extensiveness that were studied in the Phase 3 clinical trials.”
BackgroundSelf-citationBüller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353 · cited 1×
“were open-label,[36,37] but the trials for dabigatran, apixaban and edoxaban were double-blind.”
BackgroundOral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324 · cited 1×
“[38–40] There is also wide variation in treatment duration, the proportion of unprovoked/provoked VTE cases, the number of PE patients and the disease extensiveness that were studied in the Phase 3 clinical trials.”
BackgroundEdoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869 · cited 10×
“Sources: Resource use data are from a post hoc analysis of the Hokusai-VTE study [5]; cost data are from an analysis of the Premier Hospital Database 2009–2011.”
BackgroundMethodInfluentialCost-Effectiveness in Health and Medicine
(2016) · doi:10.1093/acprof:oso/9780190492939.001.0001 · Cited by 1,552 · cited 1×
“[8] Based on U.”
Beckman, M. G., Hooper, W. C., Critchley, S. E., & Ortel, T. L. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2009.12.017 · Cited by 1,055 · cited 1×
“[2] As risk factors for VTE such as advanced age, immobility, surgery and obesity become increasingly prevalent in the United States, the incidence of VTE and related deaths is likely to double by the year 2050.[3,4] The Hokusai-VTE trial, a Phase 3 clinical trial of 8240 patients, demonstrated that edoxaban administe…”
BackgroundPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Self-citationTreatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
Self-citationPrandoni, P., Noventa, F., Ghirarduzzi, A., Pengo, V., Bernardi, E., Pesavento, R., Iotti, M., Tormene, D., Simioni, P., & Pagnan, A. (2007) · Haematologica · doi:10.3324/haematol.10516 · Cited by 776
What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation?
Ubel, P. A., Hirth, R. A., Chernew, M. E., & Fendrick, A. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1637 · Cited by 588 · cited 1×
“[7] It should be noted that while the $50,000 threshold is often used, greater thresholds may be considered.[16,25,26]”
BackgroundBraithwaite, R. S., Meltzer, D. O., King, J. T., Leslie, D., & Roberts, M. S. (2008) · Medical Care · doi:10.1097/mlr.0b013e31815c31a7 · Cited by 579 · cited 1×
“[7] It should be noted that while the $50,000 threshold is often used, greater thresholds may be considered.[16,25,26]”
BackgroundEriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522 · cited 1×
“Furthermore, differences in the pharmacological and pharmacokinetic profiles [41] also led to differences in dosing frequency and food–drug interactions across the NOACs.”
BackgroundAnderson, J. L., Heidenreich, P. A., Barnett, P. G., Creager, M. A., Fonarow, G. C., Gibbons, R. J., Halperin, J. L., Hlatky, M. A., Jacobs, A. K., Mark, D. B., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000042 · Cited by 519
Baker, W. L., Cios, D. A., Sander, S. D., & Coleman, C. I. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.3.244 · Cited by 411 · cited 1×
“patients receiving warfarin anticoagulation in clinical practice.[29] Therefore, an analysis based on the data from the Hokusai-VTE clinical trial might have underestimated the cost-effectiveness of edoxaban relative to warfarin in realworld clinical practice.”
MethodChronic Thromboembolic Pulmonary Hypertension
Piazza, G., & Goldhaber, S. Z. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910203 · Cited by 410
Self-citationLuo, N., Johnson, J. A., Shaw, J. W., Feeny, D., & Coons, S. J. (2005) · Medical Care · doi:10.1097/01.mlr.0000182493.57090.c1 · Cited by 383 · cited 1×
“87.[13] Disutility values for each acute event were applied within the cycle in which the event occurred.”
MethodBoutitie, F., Pinede, L., Schulman, S., Agnelli, G., Raskob, G., Julian, J., Hirsh, J., & Kearon, C. (2011) · BMJ · doi:10.1136/bmj.d3036 · Cited by 371 · cited 1×
“[22].”
Heit, J. A., Cohen, A. T., Anderson, F. A., & on Behalf of the VTE Impact Assessment Group (2005) · Blood · doi:10.1182/blood.v106.11.910.910 · Cited by 345 · cited 1×
“with an estimated 296,370 VTE-related annual deaths.[1] PE is the third most common cause of death in patients with cardiovascular disease (following myocardial infarction and stroke).”
BackgroundEconomic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome
MacDougall, D. A., Feliu, A. L., Boccuzzi, S. J., & Lin, J. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060388 · Cited by 300 · cited 1×
“Estimates for post-ICH cost ($2764) were obtained from the literature.[18,24] The two evaluated treatment options in the model were the following: (1) edoxaban (60 mg once daily) with a 5-day heparin lead-in (enoxaparin 80 mg/0.”
MethodPost‐thrombotic syndrome: prevalence, prognostication and need for progress
Prandoni, P., & Kahn, S. R. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07601.x · Cited by 279 · cited 1×
“Hence, we did not consider the costs and consequences of longer-term complications such as severe postthrombotic syndrome and chronic thromboembolic pulmonary hypertension that are associated with recurrent VTE events.[31,32] Notwithstanding these limitations, our findings are similar to other recent studies that foun…”
ResultPrevalence of clinical venous thromboembolism in the USA: Current trends and future projections
Deitelzweig, S. B., Johnson, B. H., Lin, J., & Schulman, K. L. (2011) · American Journal of Hematology · doi:10.1002/ajh.21917 · Cited by 244
Romualdi, E., Donadini, M. P., & Ageno, W. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.62 · Cited by 129 · cited 1×
“Because VTE patients have a long-term risk of recurrence, treatment beyond 1-year and in some cases lifelong is warranted.[30] Our study is limited to model duration of 1 year due to data”
BackgroundEdoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 105 · cited 4×
“The objective of this study was to evaluate the cost-effectiveness of edoxaban versus warfarin for the treatment of adults with VTE.”
BackgroundInfluentialEstimating Quality of Life in Acute Venous Thrombosis
Hogg, K., Kimpton, M., Carrier, M., Coyle, D., Forgie, M., & Wells, P. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.563 · Cited by 86 · cited 3×
“The disutility values for recurrent DVT, recurrent PE, non-ICH major bleeds and CRNM bleeds were obtained from previously published studies and VTE models [14–18] (Table 4).”
BackgroundMethodMarchetti, M., Pistorio, A., Barone, M., Serafini, S., & Barosi, G. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00793-8 · Cited by 76 · cited 1×
“015526426 [20] Reported mean (±SD) utility of 0.”
BackgroundYou, J. H. S., Tsui, K. K. N., Wong, R. S. M., & Cheng, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039640 · Cited by 70 · cited 2×
“The disutility values for recurrent DVT, recurrent PE, non-ICH major bleeds and CRNM bleeds were obtained from previously published studies and VTE models [14–18] (Table 4).”
MethodLefebvre, P., Coleman, C. I., Bookhart, B. K., Wang, S.-T., Mody, S. H., Tran, K. N., Zhuo, D. Y., Huynh, L., & Nutescu, E. A. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2013.858634 · Cited by 66 · cited 3×
“Estimates for post-ICH cost ($2764) were obtained from the literature.[18,24] The two evaluated treatment options in the model were the following: (1) edoxaban (60 mg once daily) with a 5-day heparin lead-in (enoxaparin 80 mg/0.”
BackgroundMethodChen, S., Wu, N., Gulseth, M. P., LaMori, J. C., Bookhart, B., Boulanger, L., Fields, L. E., & Schein, J. R. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.4.291 · Cited by 59 · cited 1×
“patients at high risk of VTE recurrence would be non-compliant with warfarin therapy.[28] In the Hokusai-VTE clinical trial, adherence to edoxaban treatment was 80% or more in 99% of the patients randomized to edoxaban treatment.”
BackgroundSeaman, C. D., Smith, K. J., & Ragni, M. V. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.09.015 · Cited by 44 · cited 1×
“[7] It should be noted that while the $50,000 threshold is often used, greater thresholds may be considered.[16,25,26]”
BackgroundAdherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism
Ganz, D. A., Glynn, R. J., Mogun, H., Knight, E. L., Bohn, R. L., & Avorn, J. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.91022.x · Cited by 40 · cited 1×
“Studies have shown that one in four patients would not fill prescriptions for the recommended length of treatment [27] and 77% of”
BackgroundBoutitie, F., Pinède, L., & Schulman, S. (2011) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.08.030 · Cited by 38
Canonical Notch Signaling Is Dispensable for the Maintenance of Adult Hematopoietic Stem Cells.
Maillard, I. P., Pross, S. E., Shestova, O. E., Sai, H., Aster, J. C., Bhandoola, A., & Pear, W. S. (2005) · Blood · doi:10.1182/blood.v106.11.267.267 · Cited by 35
Chen, J., & FangFang, F. A. N. (2013) · Pharmaceutical Care and Research · doi:10.5428/pcar20130417 · Cited by 34
Treatment options for venous thromboembolism: lessons learnt from clinical trials
McRae, S. J. (2014) · Thrombosis Journal · doi:10.1186/s12959-014-0027-8 · Cited by 26 · cited 1×
“NOACs cannot be compared directly given the significant differences in individual study design and patient characteristics.[35] For example, rivaroxaban’s Phase 3 clinical trials”
BackgroundColeman, C. I., Limone, B. L., Bookhart, B. K., Mody, S. H., & Nutescu, E. A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.02.006 · Cited by 18 · cited 2×
“The disutility values for recurrent DVT, recurrent PE, non-ICH major bleeds and CRNM bleeds were obtained from previously published studies and VTE models [14–18] (Table 4).”
Methodvan Leent, M. W. J., Stevanović, J., Jansman, F. G. A., Beinema, M. J., Brouwers, J. R. B. J., & Postma, M. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135054 · Cited by 17 · cited 1×
“[16–18] Dabigatran was found to be costsaving or cost-effective compared to vitamin K antagonists for the treatment of DVT in an analysis based on INR monitoring cost data from a Dutch hospital.[33] Lifetime treatment of apixaban was shown to be cost-effective compared to rivaroxaban, dabigatran and low molecular weig…”
MethodLanitis, T., Hamilton, M., Rublee, D. A., Leipold, R. J., Quon, P., Browne, C., & Cohen, A. T. (2014) · Value in Health · doi:10.1016/j.jval.2014.08.1434 · Cited by 5 · cited 1×
“[33] Lifetime treatment of apixaban was shown to be cost-effective compared to rivaroxaban, dabigatran and low molecular weight heparin/Vitamin-K antagonist in a Markov model performed from UK cost perspective.[34] These data, together with the results of the current study that showed edoxaban to be cost-effective or…”
Result
Research works printed but not linked: 1
- Murphy SL, 2013, Deaths: final data for 2010. National vital statistics reports, 61
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“All of them suggested that DOACs are costeffective relative to VKA.(100,104-116)”
BackgroundPrevention of venous thromboembolism in patients with cancer
Guntupalli, S. R., Spinosa, D., Wethington, S. L., Eskander, R. N., & Khorana, A. A. (2023) · BMJ · doi:10.1136/bmj-2022-072715 · Cited by 73
Li, A., Carlson, J. J., Kuderer, N. M., Schaefer, J. K., Li, S., Garcia, D. A., Khorana, A. A., Carrier, M., & Lyman, G. H. (2020) · Cancer · doi:10.1002/cncr.32724 · Cited by 42
“We then calculated the disutility from general medical patients with VTE, bleeding, ICH, PTS, and CTEPH and subtracted the disutility from the baseline utility weight to determine the adjusted weight for each outcome state.(24,34-36) For the primary utility measures of VTE and bleeding, we used the data published by H…”
MethodAnticoagulant Therapy for Cancer-Associated Thrombosis: A Cost-Effectiveness Analysis
Gulati, S., & Eckman, M. H. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1258 · Cited by 31
“1515 LogNormal Preblick et al and Li et al (16, 17) Recurrent DVT 9343.”
BackgroundInfluentialLi, A., Manohar, P. M., Garcia, D. A., Lyman, G. H., & Steuten, L. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.012 · Cited by 30
“[13] All cost estimates were inflated to 2018 US dollars using the US Consumer Price Index for all urban consumers’ medical care.”
Method
Metadata
- Authors
- Preblick, R., Kwong, W. J., White, R. H., & Goldhaber, S. Z.
- Affiliations
- Daiichi Sankyo (United States) (US)
- University of California Davis Medical Center (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Kwong, W. Jacqueline
- Venue
- Hospital Practice
- Publisher
- Informa UK Limited
- Published
- 2015-11-07
- Volume
- 43
- Issue
- 5
- Pages
- 249-257
- ISSN
- 0018-5809 (ISSN-L)
- 2154-8331
- 2377-1003
- OpenAlex
- W2195501587
- Cited by
- 28
- References
- 40
- Citations by year
- 2024: 1 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 3
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hospital Practice (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Daiichi-Sankyo
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- edoxaban, venous thromboembolism, cost-effectiveness, warfarin, direct oral anticoagulants, bleeding risk, quality-adjusted life years
- MeSH terms
- Adult, Anticoagulants, Cost-Benefit Analysis, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pyridines, Thiazoles, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.